Phase-II Study Evaluating Midostaurin in Induction, Consolidation and Maintenance Therapy Also After Allogeneic Blood Stem Cell Transplantation in Patients With Newly Diagnosed Acute Myeloid Leukemia Exhibiting a FLT3 Internal Tandem Duplication AMLSG 16-10

Trial Profile

Phase-II Study Evaluating Midostaurin in Induction, Consolidation and Maintenance Therapy Also After Allogeneic Blood Stem Cell Transplantation in Patients With Newly Diagnosed Acute Myeloid Leukemia Exhibiting a FLT3 Internal Tandem Duplication AMLSG 16-10

Recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Sep 2017

At a glance

  • Drugs Midostaurin (Primary) ; Cytarabine; Daunorubicin
  • Indications Acute myeloid leukaemia
  • Focus Therapeutic Use
  • Acronyms AMLSG16-10
  • Most Recent Events

    • 07 Sep 2017 Planned End Date changed from 1 Dec 2019 to 1 Jun 2020.
    • 07 Sep 2017 Planned primary completion date changed from 1 Dec 2019 to 1 Jun 2020.
    • 25 Jun 2017 Results assessing FLT3mut status at the time of diagnosis, refractory disease and relapse in acute myeloid leukemia patients treated within the CALGB 10603 (RATIFY, NCT00651261) and AMLSG 16-10 (NCT01477606) trial presented at the 22nd Congress of the European Haematology Association
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top